DNA dendrimers linked to both a targeting moiety and a siRNA which inhibits expression of Human antigen R (HuR), pharmaceutical compositions comprising the DNA dendrimers and methods of treatment and use employing the DNA dendrimers. Useful siRNA sequences are also disclosed.

The present application relates to use of Prussian blue nanoparticles in the preparation of a medicament for the prevention, delay or treatment of neurodegenerative disease. The present application finds that Prussian blue nanoparticles have significant effects in the prevention, delay or treatment of neurodegenerative disease. Cell test results show that Prussian blue nanoparticles can reduce the level of ROS in nerve cells stimulated by hydrogen peroxide and increase the proportion of living cells in nerve cells stimulated by hydrogen peroxide. Animal test results show that Prussian blue nanoparticles can significantly reduce the expression level of oxidative stress markers in the hippocampus of mouse models of neurodegenerative disease, and significantly improve the learning and memory abilities and ameliorate motor dysfunction of mouse models of neurodegenerative disease. Prussian blue nanoparticles have advantages of simple preparation process, easy for large scale production, mild reaction conditions and easy for surface modification.

Disclosed herein are interleukin (IL) conjugates (e.g., IL-2 conjugates) and use in the treatment of one or more indications. Also described herein are pharmaceutical compositions and kits comprising one or more of the interleukin conjugates (e.g., IL-2 conjugates).

The present disclosure provides methods of modulating an immune response in an individual. The present disclosure provides methods of treatment. The present disclosure provides methods comprising administering a multimeric polypeptide (synTac) and an immune checkpoint inhibitor to an individual. The present disclosure provides methods comprising administering a multimeric polypeptide (synTac) to an individual who is undergoing treatment with immune checkpoint inhibitor.

Embodiments of immunogenic conjugates including the HIV-1 Env fusion peptide and methods of their use and production are disclosed. In several embodiments, the immunogenic conjugates can be used to generate an immune response to HIV-1 Env in a subject, for example, to treat or prevent an HIV-1 infection in the subject.

The invention relates to binding molecules that bind specifically to prostate specific membrane antigen (PSMA), in particular, single human variable heavy chain domain antibodies and related methods for treatment of cancer.

This invention provides compositions and methods to treat, prevent, and diagnose viral infections. The methods provided herein involve administering polypeptides of the invention to a subject in need thereof. The viral infections can be caused by a coronavirus such as, for example, SARS-CoV-1, SARS-CoV-2 or a variant thereof. It is contemplated that the polypeptide can be further linked to a compound, wherein the compound extends the serum half-life of the polypeptide

Disclosed is a method for treating a condition associated with hyperproliferating cells, the method including the steps of administering to a subject having the condition a composition including at least one cannabinoid receptor agonist, optionally administering to the subject a photodynamic compound, and administering radiation to the subject in whom the at least one cannabinoid receptor agonist is present so as to treat the condition.

A compound for the sequestration of undesirable antibodies associated with hemophilia A, in particular when treated by factor VIII replacement therapy. The compound includes a biopolymer scaffold and at least two peptides derived from factor VIII with a sequence length of 6-13 amino acid, wherein each of the peptides independently includes a 6-amino-acid fragment of the amino-acid sequence of factor VIII, optionally wherein at most three, preferably at most two, more preferably at most one amino acid is independently substituted by any other amino acid. Also provided are pharmaceutical compositions including the compound, as well as methods for treating hemophilia A.

A compound for the sequestration of undesirable neutralizing antibodies against viral vectors in a patient. The compound includes an inert biopolymer scaffold and at least a first peptide n-mer of the general formula P ( - S - P ) .sub.(n-1) and a second peptide n-mer of the general formula P ( - S - P ) .sub.(n-1); wherein, P is a peptide with a sequence length of 2-13 amino acids and S is a non-peptide spacer, independently for each of the peptide n-mers, n is an integer of at least 1, each of the peptide n-mers is bound to the biopolymer scaffold. Independently for each occurrence, P has an amino-acid sequence including a sequence fragment with a length of at least six amino acids of a capsid protein sequence of a viral vector. Compositions including the compound and sequestering and inhibiting methods are also provided.